Cyrus Biotechnology

Cyrus Biotechnology is a private, preclinical-stage biotech leveraging a proprietary computational protein design platform to discover and develop novel biologics. The company has validated its platform through over 30 discovery programs with partners and is advancing a focused internal pipeline targeting large markets in autoimmune diseases. Its core strategy involves computationally optimizing natural proteins, such as enzymes and cytokines, to create therapeutics with superior pharmacological properties.

Integrated computational protein design platform employing novel AI algorithms (including involvement with OpenFold consortium), deep mutagenesis, and glycosylation engineering to optimize naturally existing proteins for therapeutic use.

Cyrus competes with other computationally-driven protein design companies like Generate Biomedicines, Absci, and Recursion, as well as established biotechs and pharma with strong biologics pipelines in autoimmunity (e.g., Genentech, Amgen, Horizon). Its focus on optimizing natural proteins differentiates it from some competitors generating entirely de novo designs.